Molecular mechanisms and pharmacological support of adaptation to professional activity in extreme conditions
A. O. Pyatibrat · 2016 · Doctoral dissertation. Minsk, 2016. Institute-hosted PDF, 295 pages
What this dissertation can support
Useful for generating research questions; insufficient for a dependable treatment-effect estimate, a drug ranking or a genotype-based prescribing rule.
What it adds
Human observations in a demanding field setting, placebo comparisons and measurements before and after exertion make the source more informative than a mechanism-only hypothesis. The selected Bemitil and Cortexin values suggest different functional and biochemical recovery patterns worth testing independently.
What limits confidence
- Participant flow: Figure 10 identifies a second stage. A smaller second stage can be legitimate; selection from the broader cohort is unclear, and counts within the drug comparison still disagree.
- Allocation: Randomization, allocation concealment and adequately maintained blinding are not established in the reviewed methods. Baseline similarity cannot rule out selection bias.
- Statistical comparisons: A change significant in one arm but not another does not demonstrate a difference between arms. Likewise, subgroup patterns do not establish a treatment-by-genotype interaction. Neither a reliable head-to-head drug ranking nor a validated genetic selection rule follows.
- Clinical meaning: PWC170 is an exercise-test measure. Its values do not directly demonstrate better real-world performance, fewer injuries or treatment of disease. The short recovery window cannot establish durable benefit.
- Reporting: Unreconciled denominators, differing uncertainty figures for repeated control means and an ambiguous statistical decision rule prevent confident reanalysis. Incomplete ethics metadata is not proof that approval was absent.
- Safety and transferability: A systematic harms analysis was not identified in the reviewed sections. Findings in the studied population and intranasal Cortexin preparation cannot establish long-term safety or efficacy of injectable products.
What would strengthen the evidence
A reconciled participant-flow account, documented allocation, auditable analyses comparing arms and genotype interactions, complete harms reporting and independent controlled replication. This is a source-specific editorial appraisal, not a formal systematic-review certainty rating.
Basis: selected original methods, Chapter 5 tables and narrative, Figure 10 and the final conclusions. Read the original dissertation ↗
Related evidence maps: Military & occupational ↗
Reported findings and study design
Exploratory occupational evidence. Figure 10 identifies a second-stage drug comparison, but its participant flow and the table counts remain unresolved. The significance footnotes do not identify drug-versus-placebo tests.
Figure 10 explicitly calls the 320-person drug comparison a second stage of the broader 570-person program. The difference is not by itself an arithmetic error; selection into that stage is unclear. “Group 2” retains the author’s genotype classification. Recovery is the second assessment, about three days after the field exercise. Allocation is not adequately established.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Study stages and unresolved table counts | 570 in methods; 320 in Chapter 5; Table 49 adds to 310 | Figure 10 identifies the 320-person second stage. Its selection from 570 is unclear; the 320-versus-310 discrepancy remains within that stage. |
| Cortexin Group 2 | 24 in Table 49 versus 34 in Figure 10 | The chapter gives 65 total; the table gives 31 + 24 = 55. Do not silently replace the printed count. |
| Selected recovery observations | Bemitil has more favorable work-capacity and lactate values; Cortexin has more favorable work-capacity values with limited lactate recovery. | Descriptive patterns only; see selected cells below. |
Population reconciliation — stage selection and table-count conflict
| Arm | Methods, pp. 97–98 | Second stage, p. 203 | Table 49, groups 1 + 2 |
|---|---|---|---|
| Metaprot / Bemitil | 111 | 61 | 29 + 32 = 61 |
| Cytoflavin | 113 | 63 | 31 + 32 = 63 |
| Cortexin | 115 | 65 | 31 + 24 = 55 |
| Gliatilin | 116 | 66 | 33 + 33 = 66 |
| Placebo | 115 | 65 | 30 + 35 = 65 |
Methods total 570; stated second stage 320; table total 310. Different stage sizes need a selection account, rather than being treated as inherently contradictory. Figure 10 labels Cortexin Group 2 as 34, but its caption still gives Group 2 total 156. The within-stage discrepancies remain unresolved.
Selected Group 2 recovery cells — values printed as M±m
| Measure / source table | Drug: baseline | Drug: recovery | Placebo: baseline | Placebo: recovery |
|---|---|---|---|---|
| Bemitil PWC170, W / Table 50 | 350.4±8.6 | 343.5±9.7 | 351.2±9.3 | 317.4±8.6*# |
| Bemitil lactate, mmol/L / Table 51 | 0.72±0.13 | 0.86±0.37 | 0.71±0.14 | 1.63±0.45* |
| Cortexin PWC170, W / Table 54 | 353.2±9.2 | 346.4±6.8 | 351.2±9.3 | 317.4±11.6*# |
| Cortexin lactate, mmol/L / Table 55 | 0.73±0.25 | 1.56±0.35* | 0.71±0.34 | 1.63±0.45* |
Cell symbols retained. Printed footnotes: * versus baseline; # versus Group 1, p≤0.01. These symbols are not identified as drug-versus-placebo comparisons. Table 49 gives Group 2 n=32 for Bemitil and n=35 for placebo; Cortexin n is disputed. Repeated placebo means have differing uncertainty figures in some tables; preserve the source values and do not pool or calculate confidence intervals.
These selected cells do not establish efficacy, genotype-guided treatment or comparative superiority. A within-arm change is not a between-arm effect. The source’s Cortexin discussion describes limited metabolic recovery despite functional signals. Unresolved denominators, repeated controls, statistical-reporting ambiguities and missing systematic harms reporting limit confidence.
Source for the extracted data ↗ · Checked 2026-11-06
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Figure 10 identifies 320 as a second stage of the broader 570-person program; the different stage sizes alone are not an arithmetic error. Selection into the second stage is unclear, and Table 49 adds to 310. Cortexin Group 2 is 24 in the table and 34 in Figure 10.
- One related program, not independent trials. The same placebo means recur, with differing uncertainty figures in some tables; pooling is inappropriate.
- Randomization and allocation concealment were not established. Printed significance symbols compare baseline or genotype Group 1, not explicitly drug against placebo.
- The normality decision rule printed on p. 106 appears reversed. The analysis code and implementation were not available to resolve this statistical-reporting ambiguity.
- The p. 98 ethics-reference placeholder is incomplete; p. 203 names another ethics committee without an identifier. This does not establish absence of approval.
- No systematic adverse-event table was identified in the reviewed methods and Chapter 5. Occupational observations and intranasal Cortexin cannot be transferred to injectable formulations.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: 295-page institute-hosted PDF
Review depth: Selected tables and methods visually checked; denominator reconciliation unresolved
Related-report group: pyatibrat-occupational-2012-2015. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original 295-page PDF downloaded. Tables 49–55, Figure 10 and selected methods/narrative pages visually checked. Selected recovery cells transcribed; selected final conclusions rechecked 6 November. Other tables and full participant flow were not systematically appraised.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Original dissertation text on institute host
Citation and original source
Original source: A. O. Pyatibrat. Molecular mechanisms and pharmacological support of adaptation to professional activity in extreme conditions Doctoral dissertation. Minsk, 2016. Institute-hosted PDF, 295 pages 2016.
Molekul research summary: https://molekul.io/research/recovery-pyatibrat-2016. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.
Bemitil
A benzimidazole-derived actoprotector, also indexed as bemethyl and Metaprot. Research spans patient asthenia, occupational settings, neuromuscular and liver studies, metabolism and preclinical safety; these are research contexts, not established uses.